Cabozantinib significantly delayed progression of disease compared with everolimus in patients with advanced clear cell renal cell carcinoma.
An external validation study has confirmed that biomarkers of the mTOR pathway have prognostic value in patients with clear cell renal cell carcinoma.
In patients with non–clear cell RCC, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.
Researchers have identified a key gluconeogenic enzyme, the absence of which in clear cell renal cell carcinoma (RCC) may explain the uncontrolled cell growth present in cancer cells compared with normal kidney cells.
Results of a head-to-head comparison of first-line treatment of metastatic renal cell carcinoma with the mTOR inhibitor everolimus or VEGF inhibitor sunitinib showed that everolimus did not meet noninferiority requirements as a first-line therapy.
While seven drugs have been approved for clear cell renal cell carcinoma (ccRCC) since 2005, the most appropriate systemic therapy for non-clear cell renal cell carcinoma (nccRCC) is unknown.
The order of the sequencing of sorafenib and sunitinib for first-line and second-line therapy did not affect progression-free and overall survival for patients with advanced renal cell carcinoma.